MedTrace Logo

Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

NCT01540071 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2021-05-14

Study results available
· View outcomes & findings →

Summary

This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.

Conditions

  • Castration Resistant Prostate Cancer

Interventions

DRUG

NRX 194204

NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day

Sponsors & Collaborators

  • Io Therapeutics

    lead INDUSTRY

Principal Investigators

  • Lalita Pandit, MD · Lalita Pandit, MD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2015-12-31
Completion
2015-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01540071 on ClinicalTrials.gov